DiaMedica Therapeutics Inc.

The company is a clinical-stage biopharmaceutical business developing protein therapies for individuals suffering from severe ischemic conditions. Its lead product candidate is DM199, a recombinant synthetic form of human tissue kallikrein-1 designed to improve blood flow, vascular health, and tissue perfusion. The firm focuses on clinical programs targeting preeclampsia and fetal growth restriction in pregnant women, as well as acute ischemic stroke. In addition, the organization maintains an early-stage development candidate, DM300, aimed at treating severe acute pancreatitis. Its prospective end users are patients experiencing these vascular and ischemic diseases.

The enterprise conducts clinical trials internationally rather than maintaining commercial operations. Its clinical research activities involve an ongoing study at a medical center in South Africa, preparations for clinical sites across the United States, Canada, and the United Kingdom, and a multinational stroke trial planned to enroll participants across as many as one hundred global sites. The provided text does not identify the location of the corporate headquarters.

Summary of the business section of DiaMedica Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 35 employees, all of whom were full-time employees.”